| abstract |
The present invention is directed to certain quinoline and isoquinoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing these compounds and the processes for preparing these compounds. The invention also addresses the methods of treatment of diseases mediated by the PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder and the like. |